GLPwatch
Papers (10410)
Page 136 of 174, ranked by citation count.
- Improvement of Quality of Life by Switching from Oral Semaglutide to Tirzepatide in Patients with Type 2 Diabetes.
- Rational design and evaluation of GLP-1 derivative for treating hyperglycemia combined with overexercise-induced myocardial injury.
- Effectiveness and safety of iGlarLixi in people with type 2 diabetes not at target on basal insulin and oral antidiabetic therapy in a prospective observational trial.
- [Contribution of metabolic sensors on feeding behaviour and the control of body weight].
- GLP-1RA Reduces Supraspinatus Fatty Infiltration and Promotes Functional Recovery in a Rat Model of Rotator Cuff Repair.
- The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the LIRAFLAME randomized, double-blinded, placebo-controlled trial.
- RYGB induces vagal sensory neuropathy characterized by altered Glp1r expression and enhanced exendin-4 responsiveness in male mice.
- Diagnosis and management of hyperglycaemia in patients treated with antipsychotic drugs.
- Long-term efficacy and safety of tirzepatide in participants with type 2 diabetes with inadequate glycaemic control on metformin and/or sulfonylurea: Post-hoc analysis of SURPASS-4.
- Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA.
- Gastrointestinal adverse events of semaglutide in patients with overweight or obesity.
- Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world.
- Not All GLP-1 Receptor Agonists Are Alike: Real-World Evidence of Differential Endocrine and Dermatologic Safety.
- Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis.
- Glucagon-like peptide-1 receptor agonists and hair loss: An emerging clinical concern.
- Tirzepatide therapy counters inflammatory and apoptotic responses induced by high-fat diet in rat liver.
- Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy.
- GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization.
- Patient experiences with liraglutide for obesity and binge eating disorder-A qualitative study.
- Effects of Tirzepatide Versus Basal Insulins in People With Type 2 Diabetes and Different Baseline Glycemic Patterns: Post Hoc Analyses of the SURPASS-3 and SURPASS-4 Trials.
- Glycaemic control, body weight, and safety of tirzepatide versus dulaglutide by baseline glycated haemoglobin level in Japanese patients with type 2 diabetes: A subgroup analysis of the SURPASS J-mono study.
- Tirzepatide Helps Adults With Obesity Without Diabetes Lose 15% to 21% of Their Body Weight Over 72 Weeks.
- A randomized controlled trial of once-weekly semaglutide for limiting post-smoking cessation weight gain in smokers with overweight/obesity: Study protocol.
- No More Needles: Oral Semaglutide for Weight Loss.
- Neuroprotective and cognitive benefits of Semaglutide: Insights into the underlying molecular mechanisms.
- Testing a new platform to screen disease-modifying therapy in type 1 diabetes.
- Liraglutide in islet transplantation: from bench to bedside.
- [Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)].
- Molecular Mechanisms of Liraglutide Aggregation Induced by Dual Air-Water and Silicone-Oil-Water Interfacial Stress.
- Basal insulin intensification in type 2 diabetes: a key role for GLP-1 receptor agonists.
- [Effect of Liraglutide on platelet distribution width and carotid intima-media thickness in type 2 diabetic mellitus patients with obesity].
- Long-Term Clinical and Economic Effects of Switching to Once-Weekly Semaglutide from Other GLP-1 RAs Among Patients with Type 2 Diabetes in China: A Modeling Projection Study.
- Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects.
- Association of Dulaglutide Initiation Timing With Treatment Patterns and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus in the United States.
- Different formulations of semaglutide and oxidative stress in subjects with type 2 diabetes and MASLD: an open-label, real-life study.
- Exenatide once weekly: opportunities in the primary care setting.
- Irisin and liraglutide combination therapy mitigates myocardial reperfusion injury in obese rats: Role of endoplasmic reticulum stress and apoptosis.
- Effect of bariatric surgery and pharmacological treatments on cardiovascular risk factors for adults with overweight and obesity: a systematic review and network meta-analysis.
- Ischemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk.
- Glucagon-Like Peptide-1 Receptor Agonists Combined With Personalized Digital Health Care for the Treatment of Metabolic Syndrome in Adults With Obesity: Retrospective Observational Study.
- Weekly Journal Scan: improved renal outcomes by semaglutide in patients with chronic kidney disease and type 2 diabetes in FLOW trial.
- Effects of Tirzepatide on Skeletal Muscle Mass in Adults: A Systematic Review.
- The prostaglandin E<sub>2</sub> EP3 receptor has disparate effects on islet insulin secretion and content in β-cells in a high-fat diet-induced mouse model of obesity.
- A LEADER in the management of type 2 diabetes and cardiorenal disease.
- Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
- Evaluating the efficacy and safety of survodutide for obesity: a systematic review and meta-analysis of randomized controlled trials.
- Endocrine and metabolic effects of Glucagon like peptide 1 receptor agonists (GLP1RA).
- Letter by Xie et al Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial".
- Differentiation of Microencapsulated Neonatal Porcine Pancreatic Cell Clusters in Vitro Improves Transplant Efficacy in Type 1 Diabetes Mellitus Mice.
- Pre-immunization of diet-induced obese male mice with inactivated pathogens increases power in a liraglutide intervention study.
- Clinical Potential of GIP in Type 2 Diabetes and Obesity.
- Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study.
- Research digest.
- Tirzepatide-Induced Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Presenting With Seizures.
- Unveiling the Therapeutic Potential of Dulaglutide in Mitigating Tacrolimus-Induced Nephrotoxicity Through Targeting the miR-22/HMGB-1/TLR4/MyD88/NF-κB Trajectory.
- Efficacy of Semaglutide as Adjuvant Treatment for Sleeve Gastrectomy: A Proof-of-Concept Study in Mice.
- Semaglutide and weight loss - A concern for diabetics and pharmaceuticals.
- SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins.
- A case of euglycaemic diabetic ketoacidosis in a T2DM patient using Tirzepatide.
- Adverse effects with semaglutide: a protocol for a systematic review with meta-analysis and trial sequential analysis.